Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 3188-3192

  Peric, Mihaela ^a   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; WCK 771;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES VULGATUS; CLOSTRIDIUM; DILUTION; EGGERTHELLA LENTA; FUSOBACTERIUM NECROPHORUM; FUSOBACTERIUM NUCLEATUM; FUSOBACTERIUM VARIUM; LACTOBACILLUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PORPHYROMONAS; PREVOTELLA BIVIA; PREVOTELLA INTERMEDIA; PREVOTELLA MELANINOGENICA; PRIORITY JOURNAL; PROPIONIBACTERIUM;

ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 3342882484     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.3188-3192.2004     Document Type: Article

References (20)

1. Appelbaum, P. C., A. Philippon, M. R. Jacobs, S. K. Spangler, and L. Gutmann. 1990. Characterization of β-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in β-lactam resistance. Antimicrob. Agents Chemother. 34:2169-2176.
2. Appelbaum, P. C., S. K. Spangler, and M. R. Jacobs. 1990. β-Lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides and 129 fusobacteria from 28 U.S. centers. Antimicrob. Agents Chemother. 34:1546-1550.
3. Appelbaum, P. C., S. K. Spangler, G. A. Pankuch, A. Philippon, M. R. Jacobs, R. Shiman, E. J. C. Goldstein, and D. Citron. 1994. Characterization of a β-lactamase from Clostridium clostridioforme. J. Antimicrob. Chemother. 33:33-40.
4. Bachoual, R., L. Dubreuil, C.-J. Soussy, and J. Tankovic. 2000. Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin. Antimicrob. Agents Chemother. 44:1842-1845.
5. Barry, A. L., and P. C. Fuchs. 1991. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob. Agents Chemother. 35:955-960.
6. Barry, A. L., P. C. Fuchs, D. M. Citron, S. D. Allen, and H. M. Wexler. 1993. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J. Antimicrob. Chemother. 31:893-900.
7. Bauernfeind, A. 1993. Comparative in vitro activities of the new quinolone, Bay y3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J. Antimicrob. Chemother. 31:505-522.
8. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
9. Ednie, L. M., M. R. Jacobs, and P. C. Appelbaum. 1998. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob. Agents Chemother. 42:2459-2462.
10. Golan, Y., L. A. McDermott, N. V. Jacobus, E. J. C. Goldstein, S. Finegold, L. J. Harrell, D. W. Hecht, S. G. Jenkins, C. Pierson, R. Venezia, J. Rihs, P. Iannini, S. L. Gorbach, and D. R. Snydman. 2003. Emergence of fluoroquinolone resistance among Bacteroides species. J. Antimicrob. Chemother. 52:208-213.
11. Goldstein, E. J. C., and D. M. Citron. 1992. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and Win 57273 against anaerobic bacteria. Antimicrob. Agents Chemother. 36:1158-1162.
12. Hoellman, D. B., L. M. Kelly, M. R. Jacobs, and P. C. Appelbaum. 2001. Comparative antianaerobic activity of BMS 284756. Antimicrob. Agents Chemother. 45:589-592.
13. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved standard. NCCLS publication M11-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Oh, H., and C. Edlund. 2003. Mechanisms of quinolone resistance in anaerobic bacteria. Clin. Microbiol. Infect. 9:512-517.
15. Oh, H., N. El Amin, T. Davies, P. C. Appelbaum, and C. Edlund. 2001. GyrA mutations associated with quinolone-resistance in Bacteroides fragilis group strains. Antimicrob. Agents Chemother. 45:1977-1981.
16. Peterson, M. L., J. C. Rotshafer, and L. J. V. Piddock. 2003. Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis. J. Antimicrob. Chemother. 52:481-484.
17. Ricci, V., M. L. Peterson, J. C. Rotschafer, H. Wexler, and L. J. V. Piddock. 2004. Role of topoisomerase mutations and efflux in fluroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants. Antimicrob. Agents Chemother. 48:1344-1346.
18. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
19. Summanen, P., E. J. Baron, D. M. Citron, C. A. Strong, H. M. Wexler, and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual, 5th ed. Star Publishing Co., Belmont, Calif.
20. Wexler, H. M., E. Molitoris, D. Molitoris, and S. M. Finegold. 1996. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob. Agents Chemother. 40:2232-2235.